Treatment in childhood central nervous system demyelinating disorders


KONUŞKAN B. , Anlar B.

DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, vol.61, no.11, pp.1281-1289, 2019 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 61 Issue: 11
  • Publication Date: 2019
  • Doi Number: 10.1111/dmcn.14228
  • Title of Journal : DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY
  • Page Numbers: pp.1281-1289

Abstract

The last two decades witnessed significant advances in the treatment of acquired demyelinating disorders: thirteen new agents have been approved for the treatment of multiple sclerosis in adults by the European Medicines Agency and US Food and Drug Administration in the last twenty years. Although the long-term efficacy and safety profiles of some new drugs are still being assessed in paediatric MS, clinicians may have to use them in the management of paediatric onset MS resistant to first-line medications, based on results obtained in adult-onset disease. This review summarizes the current approach to treatment in children with demyelinating syndromes. What this paper adds